CEACAM7 Antibody (6D310): sc-70837

CEACAM7 Antibody (6D310) is a mouse monoclonal IgG1 antibody that detects CEACAM7 in human samples through immunofluorescence (IF) and flow cytometry (FCM) applications. CEACAM7, also known as carcinoembryonic antigen gene-family member 2 (CGM2), is a crucial member of the carcinoembryonic antigen (CEA) family, widely recognized for its role as a tumor marker in serum immunoassays for carcinoma. CEACAM7 is primarily located on the apical surface of highly differentiated epithelial cells in the colorectal mucosa and on isolated ductal epithelial cells within the pancreas. CEACAM7′s localization suggests a role in maintaining epithelial integrity and mediating interactions with microbial populations, essential for gut homeostasis and immune response. CEACAM7 has been shown to interact with CD66a, a biliary glycoprotein, highlighting involvement in cell adhesion and signaling pathways that may influence tumorigenesis. Downregulation of CEACAM7 in colorectal cancers indicates potential as a biomarker for cancer progression and a target for therapeutic strategies. Anti-CEACAM7 antibody (6D310) is an invaluable tool for researchers investigating CEACAM7′s role in cancer biology and epithelial-microbial interactions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CEACAM7 Antibody (6D310) References:

1. Four carcinoembryonic antigen subfamily members, CEA, NCA, BGP and CGM2, selectively expressed in the normal human colonic epithelium, are integral components of the fuzzy coat.  |  Frängsmyr, L., et al. 1999. Tumour Biol. 20: 277-92. PMID: 10436421
2. Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas.  |  Schölzel, S., et al. 2000. Am J Pathol. 156: 595-605. PMID: 10666389
3. Structure of the N-terminal dimerization domain of CEACAM7.  |  Bonsor, DA., et al. 2015. Acta Crystallogr F Struct Biol Commun. 71: 1169-75. PMID: 26323304
4. Reliability of walking and stair climbing kinematics in a young obese population using a standard kinematic and the CGM2 model.  |  Horsak, B., et al. 2021. Gait Posture. 83: 96-99. PMID: 33129173
5. CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma.  |  Raj, D., et al. 2021. Clin Cancer Res. 27: 1538-1552. PMID: 33479048
6. CEACAM7 polymorphisms predict genetic predisposition to mortality in post-surgical septic shock patients.  |  Pérez-García, F., et al. 2022. J Microbiol Immunol Infect. 55: 540-544. PMID: 34657826
7. CEACAM7 expression contributes to early events of pancreatic cancer.  |  Dhasmana, A., et al. 2024. J Adv Res. 55: 61-72. PMID: 36828119
8. CGM2, a member of the carcinoembryonic antigen gene family is down-regulated in colorectal carcinomas.  |  Thompson, J., et al. 1994. J Biol Chem. 269: 32924-31. PMID: 7806520
9. Down-regulation of carcinoembryonic antigen family member 2 expression is an early event in colorectal tumorigenesis.  |  Thompson, J., et al. 1997. Cancer Res. 57: 1776-84. PMID: 9135022
10. Expression of four CEA family antigens (CEA, NCA, BGP and CGM2) in normal and cancerous gastric epithelial cells: up-regulation of BGP and CGM2 in carcinomas.  |  Kinugasa, T., et al. 1998. Int J Cancer. 76: 148-53. PMID: 9533775

The preferred pan CEA antibody is pan CEA Antibody (H-8): sc-48364.